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Abstract
Background & Methods: Recombinant factor VII (rFVII), the precursor molecule for recombinant activated FVII (rFVIIa),
is, due to its need for complex post translational modifications, produced in mammalian cells. To evaluate the
suitability of a human cell line in order to produce rFVII with post-translational modifications as close as possible to
pdFVII, we compared the biochemical properties of rFVII synthesized in human embryonic kidney-derived (HEK)293
cells (HEK293rFVII) with those of rFVII expressed in Chinese hamster ovary (CHO, CHOrFVII) and baby hamster kidney
(BHK, BHKrFVII) cells, and also with those of plasma derived FVII (pdFVII), using various analytical methods. rFVII was
purified from selected production clones derived from BHK, CHO, and HEK293 cells after stable transfection, and rFVII
isolates were analyzed for protein activity, impurities and post-translational modifications.
Results & Discussion: The analytical results showed no apparent gross differences between the various FVII proteins,
except in their N-linked glycosylation pattern. Most N-glycans found on rFVII produced in HEK293 cells were not
detected on rFVII from CHO and BHK cells, or, somewhat unexpectedly, on pdFVII; all other protein features were
similar. HEK293rFVII glycans were mainly characterized by a higher structural variety and a lower degree of terminal
sialylation, and a high amount of terminal N-acetyl galactosamines (GalNAc). All HEK293rFVII oligosaccharides
contained one or more fucoses (Fuc), as well as hybrid and high mannose (Man) structures.
Conclusions: From all rFVII isolates investigated, CHOrFVII contained the highest degree of sialylation and no terminal
GalNAc, and CHO cells were therefore assumed to be the best option for the production of rFVII.
Background
Patients with hemophilia A and B who have developed in-
hibitory antibodies against factor VIII (FVIII) or factor IX
(FIX), are successfully treated with by-passing agents such
as FEIBA, an activated prothrombin complex concentrate
derived from human plasma [1], or recombinant activated
factor VII (rFVIIa), to control and prevent bleeding. FVII
[UniProt: P08709] is a vitamin K dependent serine protease
of approximately 55 kDa. In its zymogen form, FVII is a
single chain protein which is cleaved once between R152
and I153 upon activation to its enzyme form FVIIa, consist-
ing of a light and a heavy chain linked by one disulfide
bond. FVII carries complex post-translational protein mod-
ifications (PTMs) including γ-carboxylation, N- and O-
linked glycosylation, and β-hydroxylation [2]. Some of these
modifications have been described as necessary for secre-
tion of rFVII [3], interaction with tissue factor (TF) [4, 5],
and platelet surface interactions between FVIIa/TF and its
substrate factor X [6].
Due to its complex PTMs, rFVII is expressed in genetic-
ally engineered mammalian cell lines and activated to
rFVIIa during purification. The modifications of rFVIIa
produced in Chinese hamster ovary (CHO) and baby ham-
ster kidney (BHK) cells have been described to differ from
those of pdFVII or FVIIa, especially in N-glycosylation. N-
glycans on pdFVII possess a higher amount of tri- and
tetra-antennary structures and a higher degree of sialylation
than CHOrFVIIa and BHKrFVIIa. BHKrFVIIa also has a
lower degree of γ-carboxylation on the eleventh Gla residue
than pdFVII [7], which does not influence biological activity
[8]. Side–by–side assessment of pdFVIIa and BHKrFVIIa
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showed similar in vitro and in vivo efficacy in rabbits [9].
O-glycans on S52 and S60 were found to differ on pdFVII
and BHKrFVII [10], and terminal N-acetyl galactosamines
(GalNAc) were detected only on BHKrFVIIa [7, 11, 12]. In
vivo studies directly comparing the pharmacokinetics of
FVII and/or FVIIa forms with dissimilar glycosylation pat-
terns without altering their protein sequence were con-
ducted in rats [13, 14] and humans [15, 16], and uniformly
showed differences between pdFVII, CHOrFVIIa, and
BHKrFVIIa, and desialylated rFVIIa versus native
BHKrFVIIa. In rats, desialylated BHKrFVIIa showed
26 % of the half-life of native BHKrFVIIa [13], and
BHKrFVIIa had an in vivo recovery (IVR) that was
56 % of that of CHOrFVIIa [14]. In a pharmacokinetics
study in healthy subjects and hemophilia patients,
CHOrFVIIa showed a significantly higher activity level
than BHKrFVII (for example, the area under the curve
of CHOrFVIIa was 1.28-fold that of BHKrFVIIa in
hemophilia patients) [16]. BHKrFVIIa showed a
shorter half-life and a higher volume of distribution in
FVII-deficient patients than pdFVII [15].
Several in vitro and in vivo studies demonstrated that
receptors and inhibitors are involved in binding of rFVII
and rFVIIa including the asialoglycoprotein receptor on
liver cells [17–19], and that most rFVIIa is cleared in
complex with its inhibitor antithrombin III when intra-
venously administered to hemophilia patients [20]. In
mice, the elimination kinetics of FVII were not affected
by activation and subsequent inactivation by inhibitor
complex formation [17]. rFVIIa was shown to enter the
extravascular compartment in mice after intravenous
application [21], and to be internalized into human
platelets and re-exposed again on their surface [22],
both mechanisms which might explain its prolonged
pharmacological effect beyond the circulatory half-life.
The present study evaluated the potential of using a
human cell line to synthesize a rFVII with more human-
like post-translational modifications than those derived
from rodent cell lines. Here, we describe the modifica-
tions on rFVII expressed in human embryonic kidney-
derived (HEK)293 cells compared with those of rFVII
derived from CHO and BHK cell lines and of pdFVII.
Methods
Proteins
pdFVII was purchased from Haematologic Technologies Inc.
(Essex Junction, VT, USA), commercially available rFVIIa
(NovoSeven) from NovoNordisk (Bagsvaerd, Denmark).
Expression plasmids
The construction of the plasmid vector pselp/huFVII en-
coding human FVII is described elsewhere [23]. This vec-
tor was used as a template to generate a PCR product
including a Kozak sequence for insertion via restriction
sites into a standard mammalian expression plasmid vector
containing the hygromycin resistance gene. The resulting
vector pFVIIhyg was used for mammalian cell line transfec-
tion. A murine dihydrofolate reductase (DHFR) cDNA was
cloned from the original plasmid containing the full-length
DHFR cDNA termed pAdD26SV(A)-3 [24] into an in-
house plasmid (derivative of pSV40β, Clontech, Mountain
View, CA, USA). The resulting plasmid pSVDHFR was
used as a selection plasmid for DHFR-deficient CHO cells.
Cell culture
BHK (BHK-21; ATCC#CCL-10™) and HEK293 cells
(ATCC#1531) were provided by the American Type
Culture Collection (Manassas, VA, USA), CHO DXB11
by Columbia University, New York. All cells were culti-
vated in DMEM/Ham’s F12 medium (Life Technologies,
Carlsbad, CA, USA) containing 2–10 % fetal bovine
serum (FBS, PAA, Linz, Austria). BHK and HEK293 cells
were transfected with the plasmid vector pFVIIhyg using
calcium phosphate co-precipitation [25]. Producer clones
were selected by antibiotic resistance and limited dilution
cloning. CHO DXB11 cells were co-transfected with hu-
man FVII- and murine dihydrofolate-reductase-encoding
plasmids pFVIIHyg and pSVDHFR by calcium phosphate
co-precipitation, and cultivated in DMEM/Ham’s F12 lack-
ing the purine and pyrimidine precursors hypoxanthine,
glycine, and thymidine, and containing dialyzed FBS (PAA).
Producer clones were generated by methotrexate (MTX,
Ebewe, Unterach, Austria) gene co-amplification [26]
followed by limited dilution cloning, and selected according
to cell-specific productivities and high antigen and activity
titers at low pre-activation, and to band pattern in SDS-
PAGE. rFVII was produced from cell lines growing adher-
ently in roller bottles or triple-T-flasks (both from Nunc,
Thermo Fisher Scientific, Waltham, MA, USA) after with-
drawing FBS, and, after washing cells once with phosphate-
buffered saline without Ca and Mg (Life Technologies), in
medium containing 10 μg/mL vitamin K1 (Sigma, St. Louis,
MO, USA) for 24 h. Harvests were taken every 24 h for up
to 1 week.
Purifications
Filtered cell culture supernatants containing rFVII were
purified using multiple sequential ion-exchange chroma-
tography steps.
Protein activity and concentration
FVII activity was measured by prothrombin time (PT)
clotting assay using FVII-deficient plasma and STA
Neoplastin Plus (both from Roche, Basel, Switzerland) as
activator. The FVII reference and control standards, and
imidazole dilution buffer containing 1 % human serum
albumin were from Baxter (Vienna, Austria). The refer-
ence and control standards had been calibrated against
Böhm et al. BMC Biotechnology  (2015) 15:87 Page 2 of 15
the 1st or 2nd International Standard for FVII concen-
trate. FVII pre-activation in culture supernatants was
measured using a soluble truncated rTF as FVIIa-
selective cofactor [27] by STACLOT FVIIa-rTF-kit
(Diagnostica Stago, Asnieres, France), including FVII de-
ficient plasma, recombinant soluble TF-phospholipids,
and a FVIIa calibrator and controls. All clotting assays
were performed on a STA compact automated coagul-
ometer (Diagnostica Stago). FVII-antigen was measured
by enzyme-linked immunoassay (ELISA) in 96-
microwell plates (Thermo Scientific, Waltham, MA,
USA) using sheep polyclonal antibodies (Enzyme
Research Laboratories, South Bend, IN, USA, and
Cedarlane, Burlington, ON, Canada) against human
FVII for capture and detection, the latter conjugated to
horse-radish peroxidase. pdFVII was used as a standard
to establish a calibration curve.
SDS-PAGE and Western blotting
Impurity screening of cell culture supernatants from se-
lected clones and of the purified FVII preparations was car-
ried out using SDS-PAGE with Western blotting. If not
otherwise stated, chemicals were from Sigma. Molecular
mass standards were from BioRad (Hercules, CA, USA).
For Western blotting of cell culture supernatants, 50 ng
FVII-antigen per lane from each FVII(a) sample were run
on a 12 % bis/tris SDS-PAGel (NuPage, Life Technologies)
at reducing conditions using dithiothreitol (DTT). The
proteins contained in the gels were then blotted onto a
nitrocellulose membrane (GE Healthcare, Uppsala,
Sweden) for staining with a sheep anti-human FVII
polyclonal affinity-purified antiserum (Affinity Biologi-
cals, Ancaster, ON, Canada) and with an alkaline
phosphatase-labeled rabbit anti-sheep IgG (H+L)
affinitiy-purified secondary antiserum (Jackson Immuno
Research, West Grove, PA, USA). Membranes were de-
veloped using BCIP/NBT. For impurity detection by sil-
ver staining, 220 ng per lane purified rFVII(a) was run
on an 8 – 18 % gradient tris/acetate SDS-PAGel (Excel-
Gel kit, GEHealthcare) at reducing conditions and
stained.
Monosaccharide analysis
Monosaccharide analysis of FVII was performed with and
without PNGaseF digestion to differentiate between N-
and O-glycan originating components. All samples were
desalted by acetone precipitation. For O-glycan monosac-
charide composition, samples were digested with PNGase
F (Prozyme, Hayward, CA, USA) at 37 °C overnight. Liber-
ated N-glycans were removed by ethanol precipitation. All
samples were subjected to acidic hydrolysis using 2 M
trifluor-acetic acid (TFA, Applied Biosystems, now Thermo
Fischer Scientific, Waltham, MA, USA) at 100 °C for 6 h
and subsequently vacuum dried. Separation was car-
ried out by ion exchange HPLC on a CarboPac PA20
column [28] using 4 mM sodium hydroxide under iso-
cratic conditions with pulsed amperometric detection
(HPAEC-PAD, Dionex, Sunnyvale, CA, USA).
Oligosaccharide profiling
Oligosaccharides resembling sialylated and asialo N-
glycans were separated after enzymatic liberation from the
peptide backbone by high pH anion exchange chromatog-
raphy and recorded using pulse amperometric detection
(HPAEC-PAD) similarly as in [29]. The FVII preparations
were desalted using acetone precipitation. After
lyophilization of the protein pellet the samples were recon-
stituted in 50 mM sodium phosphate buffer pH 7.5 and in-
cubated overnight with 6 mU PNGase F (Sigma) at 37 °C.
Liberated N-glycans were isolated using ethanol precipita-
tion. N-glycans were reconstituted in a water/acetic acid
mixture and incubated at room temperature for 2 h. The
samples were then vacuum dried and dissolved in water
before measurement. Separation was performed by ion ex-
change HPLC using a CarboPac PA100 column (Dionex)
with a sodium acetate/sodium hydroxide gradient with
pulsed amperometric detection (Dionex).
Sequence and post-translational modification analysis
by LC-MS
Peptide maps of FVII-isolates were generated by chro-
matographic separation of tryptic peptides, and subse-
quent mass spectrometric analysis enabled relative
Table 1 Productivities of rFVII from BHK-, CHO- and HEK293-clones after two and three cloning rounds











rFVIIa per IU rFVII [%]
BHK 2 96 6 0.7 ± 0.2 0.5 ± 0.1 2.5 ± 0.5
3 150 22 0.6 ± 0.3 1.1 ± 0.4 1.2 ± 0.9
CHO 2 143 7 1.0 ± 0.8 1.7 ± 1.8 8.3 ± 1.9
3 198 46 5.7 ± 3.5 6.7 ± 3.1 5.6 ± 2.6
HEK293 2 235 36 5.8 ± 3.0 4.7 ± 1,6 4.2 ± 2.9
3 132 35 6.7 ± 3.7 4.1 ± 2.4 11.6 ± 19.3
Mean values and standard deviations are shown for finally characterized clones obtained by limited dilution cloning. rFVII secreted into cell-culture supernatants
was determined using a PT clotting assay, and the amount of pre-activated rFVIIa by STA-clot FVIIa-rTF assay. Supernatants were harvested after 24-h secretion
into medium not containing FBS (see Methods)
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quantification of γ-carboxylation, β-hydroxylation, and
of N-linked and O-linked glycans. Tryptic digest was
carried out using 50 μg of each FVII preparation. Sam-
ples were reduced by DTT (Sigma) and alkylated by
iodoacetic acid (Sigma) prior to digestion. Tryptic diges-
tion was carried out in 50 mM ammonium-bicarbonate
buffer pH 8.4 (ammonium bicarbonate from Fluka) by
addition of 2.5 μg trypsin (Roche) at 37 °C for 18 h. The
reaction was stopped by addition of phosphoric acid.
Tryptic peptides were separated by reversed phase
HPLC (Agilent, Santa Clara, CA, USA) using a Jupiter
C18 column (Phenomenex, Torrance, CA, USA) with an
acetonitrile/water/TFA gradient coupled on-line to an
electrospray-QTOF-MS (QTOFmicro, Waters, Milford,
MA, USA). Detection was carried out using a diode
array detector (Agilent) at 214 nm (scan width from 190
to 600 nm). All relative quantifications of the respective
non-modified and modified peptides were performed in
the positive ion mode with an acceleration voltage of
30 V and scanning range of 300 – 2,000 Da, and were
analyzed with MassLynx 4.0 software (Waters). Internal
calibration was carried out via ammonium phosphate
clusters. Theoretical masses of post-translationally modi-
fied peptides were calculated manually using Excel 2007
software (Microsoft, Redmond, WA, USA). N-glycan struc-
tures were drawn using GlycoWorkBench software [30].
Results
Expression of rFVII in mammalian and human cell lines
Human rFVII derived from BHK, CHO, and HEK293
cells was produced at laboratory scale, and purified from
culture supernatants. Producer cell lines were generated
after several rounds of limited-dilution cloning, and de-
rived from single cells. Specific clotting activities deter-
mined by PT clotting assay and antigen concentrations
for rFVII preparations and pdFVII were ~2 kU/mg
(Table 2). Cell-specific productivities of HEK293 and
BHK cell clones were directly comparable using the
same vector configuration and media, whereas CHO cell
clone expression levels were augmented by gene co-
amplification by stepwise concentration increases of the
DHFR inhibitor MTX. The statistics of average rFVII
productivities achieved by all three cell lines are summa-
rized in Table 1 for a representative cell line develop-
ment campaign. After three rounds of limited dilution
cloning, BHK clones produced approximately one tenth
of the average amount of rFVII per mL culture medium
and day as produced by HEK293 and amplified CHO
clones, which was similar. The level of pre-activation
varied substantially within individual clones (ranges for
clones from the third cloning round: CHO from 2 to
11 %, BHK from undetectable to 4 %, HEK293 from un-
detectable to 85 %). Appropriate clones for production
of rFVII had therefore to be carefully selected for this
parameter. The structural integrity of CHOrFVII and
HEK293rFVII secreted into supernatants by selected
clones was assessed by immunoblotting after SDS-
PAGE; bands representing free light or heavy chains in
Fig. 1 SDS-PAGE analysis of rFVII in cell culture supernatants and
after purification. a Western blot after SDS-PAGE stained for human
FVII: lane 1: molecular mass marker. pdFVII (lane 2), pdFVIIa (lane 3),
commercially available rFVIIa (lane 4), supernatants from CHOrFVII
clones (lanes 5–7) and from HEK293rFVII clones (lanes 8–10). 50 ng
rFVII based on antigen were loaded per lane and resolved under
reducing conditions by SDS-PAGE. Human FVII was detected by
dual-antibody staining after blotting on a nitrocellulose membrane.
Molecular mass marker sizes are shown on the left. b Silver-stained
SDS-PAGE: 220 ng per lane each purified HEK293rFVII (lane 1),
commercially available rFVIIa (lane 2), were resolved by SDS-PAGE and
protein bands were made visible by silver staining. M: molecular mass
standard, molecular mass marker sizes are shown on the left.. The FVII
whole molecule, the heavy (HC) and light chain (LC) of rFVIIa are
marked with arrows
Böhm et al. BMC Biotechnology  (2015) 15:87 Page 4 of 15
reducing gels indicated no remarkable differences in
fragmentation or pre-activation between selected clones
from both cell types (Fig. 1a).
rFVII was purified from cell culture supernatants in a
multiple-step chromatographic procedure using ion-
exchange resins at step yields of >50 %, resulting in 95 %
pure rFVII as estimated from SDS-PAGE analysis apply-
ing silver staining or anti FVII Western blotting. SDS-
PAGE analysis of purified HEK293rFVII compared with
commercially available rFVIIa using silver staining is
provided in Fig. 1b.
Protein characterization
Supernatants of four clones from HEK293 and two
clones from CHO and one from BHK were purified in-
dependently and analyzed for post-translational modifi-
cations. Mean values for all parameters are shown in
Table 2, except for N-glycan analysis which is shown in
Figs. 2, 3a and b and 4. Apart from N-glycosylation,
identical protein structures and insignificantly different
post-translational modifications were detected between
rFVII from BHK, CHO, and HEK293 cells, and pdFVII.
Tryptic peptide analysis resulted in highly similar pep-
tide maps for all FVII-isolates, demonstrating primary
amino acid sequence identity (Fig. 5). The absence of
propeptide was confirmed for all isolates by LC-MS. De-
grees of γ-carboxylation were assessed by LC-MS for the
tryptic peptides representing the Gla domain which
showed, in all cases, eight fully modified Gla residues.
The ninth Gla was modified by 96 – 98 % in all FVII iso-
lates, and the tenth Gla similarly modified by 50 % in all
rFVII isolates (BHKrFVII: 53 % (n = 1 clone); CHOrFVII:
53 % (mean of 2 clones); HEK293rFVII: 56 ± 3.7 %;
mean ± standard deviation of 4 clones), and by 82 % in
pdFVII. A comparison of mass spectra of peptides T1-5
and T1-6 from all FVII isolate samples is given in Fig. 6a
and b. Raw data from LC-MS are provided in the
Additional file 1: Table S1A-D. Clonal variability is
shown in Additional file 1: Table S2. The frequency of β-
hydroxylation of D63 was similar within rFVII isolates
but higher (~10 %) than for pdFVII (<1 %).
The distribution of O-glycosylation structures analyzed
at the peptide level by LC-MS was similar for all rFVII
and pdFVII isolates except BHKrFVII which had a lower
degree of xylose (Xyl). Figure 7 shows the mass spectra
of the peptide T7 containing O-glycosylation sites S52
and S60 for all FVII isolates. Raw data from LC-MS for
O-glycosylation are provided in Additional file 1: Tables
S3A-D. rFVII with a single glucose (Glc) on S52 and a
single fucose (Fuc) on S60 was the major form in
BHKrFVII (50 %). pdFVII contained 60–70 % of Xyl-
containing oligosaccharides on S52 similarly as described
in [11], as did CHOrFVII and HEK293rFVII. The presence
of Glc and Xyl was confirmed by monosaccharide analysis.
Oligosaccharide profiling by HPAEC-PAD revealed
typically charged peak groups corresponding to 0 to 4
sialic acids on the N-glycans of CHO, BHK-derived
rFVII, and HEK293rFVII (Fig. 3). CHOrFVII and
BHKrFVII showed a similar N-glycan pattern, which
was different to that for HEK293rFVII, whose main
structures were composed of neutral to di-sialylated
N-glycans at a higher diversity.
The two N-glycosylation sites, one each on the heavy
(N322) and the light chain (N145), were characterized
by LC-MS of relevant modified peptides after tryptic di-
gestion. Sialic acid quantification was done by calcula-
tion from the LC-MS data.. The degree of sialylation on
our pdFVII preparation was 4.06 sialic acids per mol-
ecule for pdFVII (1.93 on N145 and 2.13 on N322).
These values were lower for the light chain and almost
equal for the heavy chain as described in the literature
(2.55 on N145 and 2.10 on N322, and in total 4.65,
Table 2 Summary of protein characteristics and post-translational modifications of pdFVII and rFVII from three cell lines
pdFVII CHOrFVII HEK293rFVII BHKrFVII
rFVII specific activity calculated from
PT clotting values per mg protein
(antigen) [1000 IU/mg]




γ-carboxylation of E35; i.e. abundance
of 10th Gla [%]
82 % 53 % 56 % 53 %
Presence of propeptide Not detected by peptide mapping
Hydroxylation of D68 [%] <1 % 9 % 7 % 15 %
O-glycosylation on S52 / S60;
only three major identified
types shown [%]
31 %: Glc(Xyl)2 / Fuc 56 %: Glc(Xyl)2 / Fuc 62 %: Glc(Xyl)2 / Fuc 21 %: Glc(Xyl)2 / Fuc
27 %: GlcXyl / Fuc 7 %: GlcXyl2 7 %: GlcXyl / Fuc 50 %: Glc / Fuc
15 %: Glc / Fuc 14 %: Glc / Fuc 10 %: Glc / Fuc 12 %: Glc / -
Peptide mapping and the PTMs were done by LC-MS after tryptic digest (see Methods). The raw data for γ-carboxylation and O-glycosylation of all FVII isolates
can be found in the addional PDF file provided in Additional file 1: Tables S1 and S3, respectively. Legend: Fuc Fucose, Gla γ-carboxy glutamic acid, Glc Glucose,
IU International units, Xyl Xylose
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Fig. 2 (See legend on next page.)
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respectively) [11]. All rFVII preparations had a lower de-
gree of terminal sialic acids than pdFVII: 3.14 ± 0.06
(mean ± standard deviation; n = 2) sialic acids per mol-
ecule for CHOrFVII (1.49 ± 0.06 plus 1.65 ± 0.01), 2.96
for BHKrFVII (1.57 and 1.39, one preparation only), and
0.57 ± 0.07 (n = 4) for HEK293rFVII (0.43 ± 0.04 and
0.14 ± 0.06).
Results for relative abundances of proposed structures for
all FVII isolates are shown in Fig. 2; more detailed data are
provided in Additional file 1: Table S4A-H; representative
spectra for the peptides containing the light and heavy
chain N-glycosylation sites are shown in Fig. 3a and b.
HEK293rFVII, for which isolates from four clones were
available, showed relative standard deviations of 4 to 56 %
for each N-glycan structure. It should be noted that the
variation was a sum of clonal variation, rFVII preparation,
and analytical variation.
For pdFVII, reference values from the literature were
compared with our own findings: The majority of N-
glycans on pdFVII were complex-type bi- and tri-antennary
without core-fucosylation. The main N-glycan structure on
the light and heavy chain was identified as a complex-type
biantennary disialylated N-glycan. Sialylation was almost
complete and showed mono- to trisialylated structures. A
higher diversity of structures on the light chain site, N145,
was also found. This complexity on the light chain was also
observed on all rFVII preparations, probably due to co-
translational glycosylation of the N145 site, and post-
translational glycosylation of the N322 site [31]. On the
light chain site, we detected a lower amount of tri- and no
tetraantennary structures in our pdFVII preparation in
contrast to 1 % tetraantennary forms described in the lit-
erature [11]. On the heavy chain site, the types and
amounts of N-glycans detected were almost identical to
literature values.
The main N-glycan structure for the BHKrFVII prep-
aration on both the light (53 %) and heavy chain (46 %)
was demonstrated to be a complex-type biantennary
disialylated core-fucosylated structure. Two to 17 % of
variants of this main N-glycan structure on both N-
glycosylation sites had a varying degree of sialylation (0
to 1) or were incompletely processed. Another 18 %
were biantennary and contained a terminal N-acetyl
hexosamine (HexNAc) on one chain (galacto-type) and
0–1 terminal sialic acids on the other, or two terminal
HexNAcs (4 %) corresponding to the agalacto-type. The
HexNAcs were identified as GalNAcs by monosacchar-
ide analysis (data not shown). The relative amount of
agalacto and galacto-type N-glycans was higher on the
heavy chain. Approximately 4 % of the N-glycans was
composed of complex-type tri-antennary structures with
two or three sialic acids, and some tetra-sialylated struc-
tures close to the detection limit.
Results for the N-glycan composition of CHOrFVII
showed that, as for the BHKrFVII preparation, the
CHOrFVII main N-glycan structure was demonstrated to
be a complex-type biantennary disialylated core-
fucosylated structure on the light (49 %) and heavy chain
(65 %) followed by variants with differing degree of sialyla-
tion (0 to 1) and incompletely processed structures. In
total, 96 % of oligosaccharides on CHOrFVII were core
fucosylated, bi-antennary structures carrying no, one
(35 %) or two (57 %) sialic acid residuesor incompletely
processed variants. N-glycans on CHOrFVII showed lesser
complexity than on the other cell lines. A similar amount
of complex-type tri- and tetra-antennary, core-fucosylated
structures to those of BHKrFVII was determined (4 %), as
reflected in the oligosaccharide profiles (Fig. 4). The major
difference in BHKrFVII and CHOrFVII N-glycan compos-
ition was the absence of GalNAcs on CHOrFVII.
Almost all N-glycans on HEK293rFVII were not com-
parable with those detected on or reported for pdFVII
[11], or detected on rFVII from the other cell lines. Oligo-
saccharide mapping revealed a higher diversity and a
lower amount of acidic N-glycan structures, but mostly
neutral N-linked oligosaccharides (Fig. 4). About 20 differ-
ent structures were detected, of which only two of those
detected at higher 2 % (4 % of total structures) were ob-
served on pdFVII (a biantennary complex-type disialylated
structure, and an incomplete core-fucosylated complex-
type monosialylated structure). The main N-glycan struc-
tures on HEK293rFVII were agalacto-type biantennary
core-fucosylated with additional variable fucosylation (0 to
3) on the antennae. In total, 57 % of the identified struc-
tures belonged to this agalacto-type N-glycan variant,
which was also most prominent on the heavy chain. An-
other 25 % were biantennary galacto-type core-fucosylated,
with varying degrees of antennary fucosylation (0–1) and
sialylation (0–2). This form was the most prominent on the
light chain. The remaining 15 % were shown to be incom-
pletely processed variants, hybrid-type structures with and
without sialylation and antennary fucosylation, and high-
(See figure on previous page.)
Fig. 2 Proposed N-glycan structures on N145 and N322 for pdFVII, HEK293rFVII, BHKrFVII, and CHOrFVII. Legend: GlcNAc, Man, Gal, Fuc,
GalNAc, sialic acid (NANA). Relative abundances of N-glycan structures at each N-glycosylation site detected by LC-MS are shown. Mean
values four clones of HEK293rFVII, two clones of CHOrFVII, and values for one BHKrFVII clone and one pdFVII preparation are shown. Only struc-
tures detected at equal or higher 2 % are shown. The data for CHOrFVII, HEK293rFVII and BHKrFVII of each clone and of pdFVII can be found in
Additional file 1: Table S1 in the supplementary file
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Man structures on the light chain, which were not detected
on pdFVII, or the other rFVII preparations. As for all other
FVII preparations, the structural diversity on the light chain
N-glycosylation site (N145) was higher. The presence of
GalNAc in the HEK293rFVII preparation was revealed by
monosaccharide analysis (data not shown). The tri- and
tetra-antennary structures were close to detection limit. No
sulfated GalNAcs were detected as reported for other
HEK293-derived recombinant proteins [32].
Discussion
The post translational modifications of rFVII derived
from a human cell line e.g. the biochemical properties of
rFVII produced in HEK293 cells were compared with
those of rFVII expressed in CHO and BHK cell lines,
and of pdFVII. Single-cell derived producer cell lines
were generated, and clones selected according to growth
characteristics, rFVII productivity, activity and degree of
pre-activation. For the production of rFVII, cell culture
and purification conditions were kept equal for all three
cell lines to enable comparability of results. Although
cell culture conditions were not controlled as in a bio-
reactor, and metabolites not measured, we assume that
product qualities were comparable due to identical cell
culture and purification conditions. This comparability
was also reflected by highly similar degrees of γ-
carboxylation in all rFVII isolates (53 % carboxylation of
the 10th Gla on average in CHOrFVII and BHKrFVII,
(See figure on previous page.)
Fig. 3 a and b Mass spectra of the N-glycosylated peptides containing the light and heavy chain glycosylation sites (N145 and N322) of pdFVII
and rFVII isolated from CHO, HEK293 and BHK. a Mass spectra of the light chain peptides (N145). Relative intensities of glycan structures were
calculated based on the masses of the 3-fold positively charged peptides. b Mass spectra of the heavy chain peptides (N322) based on the 4-fold
positively charged peptides. Both mass spectra of all samples were recorded within the same system setup. Only intensities of manually identified
peaks were used for the calculation of relative amounts of N-glycan species. Major identified oligosaccharide structures are shown for each FVII isolate.
Theoretical and calculated molecular masses, and relative abundances of glycan structures can also be found in the Additional file 1: Tables S4A-H
Fig. 4 Oligosaccharide maps of BHK-, CHO-, and HEK293-derived rFVII. N-linked oligosaccharides obtained after PNGase F digest were separated according
to their charge by HPAEC with PAD. Positions of neutral and bi-antennary/mono-sialylated to tetra-antennary/tetra-sialylated structures are marked
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and a mean ± standard deviation of 56 ± 3.7 % in four
HEK293rFVII isolates). Clonal differences regarding γ-
carboxylation in the purified rFVII isolates were assessed,
as this parameter is known to be sensitive to limitations in
the cellular post-translational protein modification ma-
chinery in the secretion pathway of recombinant vitamin
K dependent coagulation factors [33]. For example, the
relative standard deviation of the four HEK293rFVII iso-
lates was 7 % for the quantification of the 10 Gla-modified
peptide, and 9 % for the 9 Gla-containing peptide. We
therefore concluded that our cell culture system was re-
peatedly able to produce rFVII from different clones and
host cell lines at similarly high quality.
Consistent with the literature [10], differences were
detected between the O-glycans on BHKrFVII and those
on the other rFVIIa isolates. The most marked differ-
ences between rFVII from the three cell types and
pdFVII were in their N-glycosylation. Unexpectedly,
most N-glycans synthetized by HEK293 on rFVII were
not comparable with those published for pdFVII [11], or
found on our own pdFVII preparation. A high percent-
age of N-glycans carrying terminal Gal and GalNAcs
(galacto- and agalacto-type) was detected in HEK293rF-
VII, a smaller degree in BHKrFVII, and only a small
fraction terminating only in Gal in CHOrFVII. Data
from our BHKrFVII characterization were in agreement
with those reported for BHK-derived rFVIIa [34].
The N-glycans on our HEK293rFVII were similar to
those described for other HEK293-derived recombinant
proteins. Croset and colleagues compared the post trans-
lational modifications of recombinant proteins expressed
in parallel in a CHO and a HEK293 host cell system.
Proteins derived from HEK293 EBNA and HEK293-6E
cell lines had similar glycostructures consisting of more
heterogenous and mostly basic isoforms compared with
CHO, indicating a lower amount of sialic acids [35]. Re-
combinant activated protein C (rAPC) derived from
HEK293 cells was shown to have 50 % fewer sialic acids
Fig. 5 Peptide maps of CHO-, HEK293-, BHK-derived rFVII, and pdFVII. Peptides were separated by HPLC on a C18 column after reduction, alkylation and
tryptic digest. Shown are chromatograms with retention times of respective peptides detected at 214 nm of one representative preparation of each FVII
isolate, all four recorded within one sequence
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than pdAPC, with most N-glycans ending in partially
sialylated GalNAc, and to contain 5-fold more Fuc [36].
APC is cleared via complex formation with its inhibitors
[37, 38] as demonstrated by a comparably short t1/2 of
rAPC (8–12 min) and pdAPC (12–15 min) in monkeys,
and 17 min in humans [39].
Other proteins derived from HEK293 have been de-
scribed: L-selectin with mainly core- and antennary-
fucosylated biantennary N-glycans terminating in either
Gal or GalNAc [40], and a human leukocyte receptor IIIa
(FcγRIIIa). The faster association and dissociation of IgG
on the CHO- than on the HEK293-derived recombinant
FcγRIIIa was attributed to the observed differences in
glycosylation [41].
It is currently unknown whether Fuc attached to the an-
tennary structures impair rFVIIa function and clearance.
As we did not clarify glycan linkages in detail, it was not
possible to verify or exclude the presence of ABH blood
group antigens on HEK293rFVII. These have been reported
to influence plasma levels of circulating von Willebrand
factor, and FVIII [42].
HEK293 cells are currently in use to develop recom-
binant protein products for hemophilia therapy, i.e. a B-
domain-deleted FVIII [43], and FVIIa-Fc, FIX-Fc, and
(See figure on previous page.)
Fig. 6 a and b Mass spectra of γ-carboxylated peptides of CHO-, HEK293-, BHK-derived rFVII, and pfVII. Shown are mass spectra of peptides
T1-5 (a) with peaks corresponding to peptides containing 8, 9, and 10 Gla residues indicated, and T1-6 (b), which mostly contained 10 Gla
residues. All spectra were recorded within one system setup. Corresponding data can also be found in Additional file 1: Tables S1A-D in the
supplementary file
Fig. 7 Mass spectra of the O-glycosylated peptide T7 detected from CHO-, HEK293-, BHK-derived rFVII, and pdFVII. Shown are masses of the T7
peptide corresponding to the peptides containing O-glycans on S52 and S60. The major forms on CHOrFVII and HEK293rFVII were GlcXyl2 on S52
and Fuc on S60, whereas BHKrFVII contained mostly one Glc on S52 and Fuc on S60, and pdFVII mostly GlcXyl or GlcXyl2 on S52 and Fuc on S60
and. Symbols: Fucose; Glucose; Xylose. In Additional file 1: Tables S3A-D, raw data can be found
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FVIII-Fc fusion proteins [44–46]. They were reported to
produce interferon-α2b which was highly similar to its
natural counterpart [47]. N-glycans on HEK293 derived
B-domain deleted FVIII were recently characterized [48].
The main structure found on pdFVIII (~50 % of N-
glycans) - a biantennary complex type terminating in
Gal capped with one or two sialic acids with and without
core fucosylation [49] - was detected in <10 % of all
HEK293rFVIII N-linked carbohydrates. Similar struc-
tures as on our HEK293rFVII, such as biantennary N-
glycans terminating in Gal and GalNAc with core and
antenna fucosylation, were found on HEK293-derived
rFVIII. A comparison of recombinant human erythro-
poietin derived from various cell lines revealed a lower
degree of sialylation for the protein from HEK293 than
from CHO or BHK cells [50].
Post translational modifications, particularly glycosyla-
tion patterns, influence the pharmacokinetics and
pharmacodynamics of recombinant proteins. Gal and Gal-
NAc have been described to bind the asialoglycoprotein
receptor with high affinity [51], leading to rapid clearance
from the circulation. We therefore assumed CHOrFVII to
be the most suitable precursor for a therapeutic rFVIIa
product as it had the highest degree of sialylation and no
terminal GalNAc. Significantly higher areas under the
curve (AUCs) for CHOrFVIIa than for BHKrFVIIa ob-
served in healthy volunteers and hemophilia patients [16]
suggest that intravenously injected HEK293rFVIIa would
remain shortest in circulation, although clinical and pre-
clinical confirmation of this assumption is lacking. In a
similar study, we showed that HEK293rFIX has a signifi-
cantly lower IVR and AUC than CHOrFIX in FIX knock-
out mice [52]. HEK293 derived recombinant ADAMTS13
exhibited a much shorter in vivo half-life in mice than
CHO produced rADAMTS13 [53]. In summary, several
studies comparing features of recombinant proteins de-
rived from HEK293 cells with those from other cell lines
or the naturally occurring form found lower degrees of
terminal sialic acids on the N-glycans, high amounts of
fucosylation, glycan forms not found on the natural coun-
terpart, and faster clearance from circulation for the
HEK293-derived protein. Another concern when using a
human cell line to produce a human therapeutic would be
human cell derived host cell contaminations. There is a
currently unknown risk that co-administration of contam-
inating human host-cell derived proteins could induce,
over time and after repeated dosing, anti-host cell protein
antibodies which might behave like human auto-
antibodies and thus increase the risk of adverse reactions
in patients.
Conclusion
In conclusion, the only major differences in post-
translational modifications between HEK293rFVII and
rFVII expressed in CHO, BHK cells and pdFVII were
in N-glycosylation, with most N-glycans on HEK293
differing from those on rFVII expressed in other two
cell lines, and, surprisingly, from pdFVII. From all
rFVII isolates investigated, CHOrFVII contained the
highest degree of sialylation and no terminal GalNAc,
with all other protein features of high quality at high
productivity, and CHO cells were therefore assumed to
be the best choice for the production of rFVII. These
results emphasize the importance of assessing the
suitability of a cell line, or a particular cell clone, for
producing human therapeutic proteins on a case-by-
case basis.
Additional file
Additional file 1: An Additional File in PDF format (“Additional
file_rFVIIthreecelltypes_ EBoehm_REVISION072015.pdf”) is provided
containing the LC-MS raw data for all FVII isolates concerning
γ-carboxylation (Tables S1 and S2), O-glycosylation (Tables S3), and
N-glycosylation (Table S4). (PDF 1065 kb)
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